Statement on the benefits of fish/seafood consumption compared to the risks of methylmercury in fish/seafood
EFSA Scientific Committee · 2015 · EFSA Journal
DOI: 10.2903/j.efsa.2015.3982View source ↗
“Fish meat, particularly tuna, swordfish, cod, whiting and pike were identified as the most important contributors of methylmercury exposure in Europe.”
Summary
This EFSA Scientific Committee statement weighs the cardiovascular and neurodevelopmental benefits of fish consumption against the risks of methylmercury exposure across the European population. It builds on EFSA's 2012 opinion which set the tolerable weekly intake (TWI) for methylmercury at 1.3 µg/kg body weight — meaning a 70 kg adult can safely consume about 91 µg/week. The 2015 statement identifies the dominant European mercury sources by species: tuna (the largest single contributor in adult diets), swordfish, cod, whiting, and pike. Notably, sardines are not on this high-mercury list. The statement acknowledges new epidemiological data (Seychelles cohort) showing that the long-chain omega-3s from fish may counteract some methylmercury toxicity — a benefit-risk tradeoff that favors lower-mercury species like sardines. EFSA's conclusion is risk-tiered: vulnerable groups (pregnant women, children, high-fish consumers up to 6× TWI) should choose lower-mercury species; the general adult population can consume fish at moderate intake without exceeding the TWI.
Talking it through with practitioners
The Inner Circle is a paid, async-first community for discussing what new evidence means for actual cycles — opening soon.
Citation graph
How this entry connects to the rest of the library
Entries that reference this one
- ExtendsEvidence on the human health effects of low-level methylmercury exposureKaragas MR et al. · 2012
Karagas 2012 provides the toxicological evidence base; EFSA 2015 integrates this with the omega-3 nutritional benefit case to derive consumption-pattern guidance.
- ExtendsFish intake, contaminants, and human health: evaluating the risks and the benefitsMozaffarian D & Rimm EB · 2006
Mozaffarian/Rimm 2006 in JAMA established the benefit-risk framework that EFSA's 2015 European-population statement updated and refined.
Tags
Not medical advice. This page summarizes primary research. It is not a substitute for consultation with a qualified clinician. See safety for exclusion criteria.